Results 151 to 160 of about 5,598,449 (384)

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement

Journal of the American Medical Association (JAMA), 2018
Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years.
D. Grossman, S. Curry, D. Owens, Kirsten Bibbins-Domingo, A. Caughey, K. Davidson, Chyke A Doubeni, M. Ebell, J. Epling, A. Kemper, A. Krist, Martha Y. Kubik, C. Landefeld, C. Mangione, Michael Silverstein, M. Simon, A. Siu, Chien-Wen Tseng   +17 more
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence

npj Precision Oncology
Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential to identify targets for development of new precision ...
Muthana Al Abo, Wen-Chi Foo, Lauren E. Howard, Shannon McGue, Bonnie Lacroix, Julie Kephart, Angela Clayton, Blair Thornburg, Monika Anand, Michael B. Rothberg, Shannon J. McCall, Jiaoti Huang, Thomas A. Esther, Judd W. Moul, Michael N. Ferrandino, Thomas J. Polascik, Cary N. Robertson, Brant A. Inman, Andrew J. Armstrong, Yuan Wu, Terry Hyslop, Daniel J. George, Steven R. Patierno, Jennifer A. Freedman   +23 more
doaj   +1 more source

Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.

, 2012
PURPOSE: Multiparametric magnetic resonance imaging can be used to guide prostate biopsy by targeting biopsies to areas in the prostate at high risk for cancer. We compared the detection of clinically significant and insignificant cancer by transperineal
Ahmed, Ahmed, Barqawi, Barzell, Bossuyt, Delongchamps, deSouza, Dickinson, Goto, Hadaschik, Haffner, Hambrock, Harnden, Hoeks, Hu, Labanaris, Lee, Miyagawa, Moore, Natarajan, Nevoux, Onik, Pinto, Prando, Puech, Rouse, Sciarra, Stamey, Tanimoto, Villers   +29 more
core   +1 more source

An Assessment of Factors Influencing Survival in Prostatic Cancer: The Absence of Reliable Prognostic Features [PDF]

, 1958
L. M. Franks, J. D. Fergusson, G F Murnaghan   +2 more
openalex   +1 more source

Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer

New England Journal of Medicine, 2018
BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA) level are at high risk for metastasis.
M. Hussain, K. Fizazi, F. Saad, P. Rathenborg, N. Shore, U. Ferreira, P. Ivashchenko, E. Demirhan, K. Modelska, D. Phung, A. Krivoshik, C. Sternberg   +11 more
semanticscholar   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

The Role of Oestrogen Therapy in the Treatment of Prostatic Cancer [PDF]

, 1948
J. D. Fergusson
openalex   +1 more source

The long tail of oncogenic drivers in prostate cancer

Nature Genetics, 2018
Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others.
J. Armenia, Stephanie A. M. Wankowicz, David Liu, Jianjiong Gao, Ritika Kundra, E. Reznik, W. Chatila, D. Chakravarty, G. Han, Ilsa M Coleman, B. Montgomery, C. Pritchard, C. Morrissey, C. Barbieri, H. Beltran, A. Sboner, Z. Zafeiriou, S. Miranda, C. Bielski, A. Penson, C. Tolonen, F. Huang, D. Robinson, Yi Mi Wu, R. Lonigro, L. Garraway, F. Demichelis, P. Kantoff, M. Taplin, W. Abida, B. Taylor, H. Scher, P. Nelson, J. Bono, M. Rubin, C. Sawyers, A. Chinnaiyan, N. Schultz, E. V. Van Allen, PCFSU2C International Prostate Cancer Dream Team   +39 more
semanticscholar   +1 more source

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source